ArticleTranslational stroke research2025
Association of Serum Neurofilament Light and Glial Fibrillary Acidic Protein with Cerebral Small Vessel Disease in Nondemented Middle-to-Old Aged Population.
Article in Translational stroke research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association Between Cognitive Impairment and Multimodal MRI Markers in Patients with Cerebral Microbleeds: A Retrospective Case-Control Study.International journal of general medicine · 2026Article
- Cerebral microbleeds on susceptibility-weighted imaging, cognitive domains, and serum neurofilament light chain in adults with hypertension.Frontiers in neurology · 2026Article
- The use of brain-specific biomarkers in urine for prediction of neurological outcome and extent of tissue damage following stroke.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Neurofilament light chain (NfL) and brain glial fibrillary acidic protein (GFAP) are promising markers for cerebral vascular damage. We aimed to evaluate if increased serum NfL and GFAP were associated with cerebral small vessel disease (CSVD) markers among the nondemented middle-to-old aged population. We included participants from the Shunyi Study who had serum NfL and GFAP measurements. Cerebral microbleeds (CMBs), lacunes, perivascular space (PVS) white matter hyperintensities volume (WMHV), and brain parenchymal fraction (BPF) were measured. Cross-sectional and longitudinal associations between CSVD imaging markers and NfL levels were evaluated using multivariable-adjusted models. We included 848 nondemented participants (mean age: 55.5 ± 8.7 years) cross-sectionaly. Among these participants, 603 underwent longitudinal analysis, with an average follow-up time of 5.59 years (range: 4.34-7.20 years). Serum NfL was positively associated with baseline lacunes (OR = 1.40, 95% CI: 1.12-1.75) and WMHV (P < 0.001). GFAP was positively associated with WMHV (P = 0.016), while the association disappeared when including NfL simultaneously in the model. CMBs, PVS, and BPF were not associated with the biomarkers. Logitudinally, baseline NfL was significantly higher among participants with incident lacunes (OR: 1.44, 95% CI: 1.07-1.92); however, this association was attenuated and lost statistical significance after further adjustment for baseline lacune. Increased serum NfL appears to be indicative of lacunes and also the progression of lacunes among middle-to-old-age population. The association between serum NfL and CSVD image markers was less pronounced in the middle-to-old-age population than in the elderly, while GFAP did not prove to be a valuable CSVD biomarker. KEY POINTS: The association between serum NfL and CSVD was less pronounced in the middle-to-old-age population than in the elderly. Serum NfL was positively associated with lacunes (OR = 1.40, 95% CI: 1.12-1.75) and WMHV (P < 0.001). Baseline serum NfL was associated with a 44% increased risk of incident lacunes over a 5.59-year follow-up, but was attenuated after controlling for baseline lacune. Other CVSD markers, including CMBs, PVS, and BPF, showed no association with either NfL or GFAP.
Indexed as
Identifiers
40450100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.